Hikma Pharmaceuticals (OTCMKTS:HKMPF) Reaches New 12-Month Low – Here’s Why

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) shares hit a new 52-week low on Friday . The company traded as low as $16.3425 and last traded at $16.3425, with a volume of 225 shares trading hands. The stock had previously closed at $18.00.

Analyst Ratings Changes

Separately, Barclays downgraded Hikma Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 6th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Hikma Pharmaceuticals presently has an average rating of “Hold”.

Hikma Pharmaceuticals Trading Down 9.2%

The company has a quick ratio of 0.72, a current ratio of 1.24 and a debt-to-equity ratio of 0.33. The stock has a fifty day moving average of $20.74 and a 200 day moving average of $21.84.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.